{"id":"megestrol-acetate-and-olanzapine","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Thromboembolic events (megestrol)"},{"rate":null,"effect":"Metabolic syndrome"},{"rate":null,"effect":"Extrapyramidal symptoms (olanzapine)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Megestrol acetate is a synthetic progestin that acts on the hypothalamus to increase appetite and caloric intake, commonly used in cachexia and wasting syndromes. Olanzapine is an atypical antipsychotic that antagonizes dopamine and serotonin receptors and has known side effects of appetite stimulation and weight gain. The combination leverages both agents' appetite-enhancing properties for synergistic benefit in conditions characterized by severe weight loss or nutritional decline.","oneSentence":"This combination uses megestrol acetate (a progestin) to stimulate appetite and promote weight gain, while olanzapine (an atypical antipsychotic) provides additional appetite stimulation and may address underlying psychiatric or behavioral symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:35.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer cachexia and weight loss in advanced malignancy"},{"name":"Appetite stimulation and nutritional support in wasting syndromes"}]},"trialDetails":[{"nctId":"NCT06500234","phase":"PHASE3","title":"Nutrition Impact on Immunotherapy of Cancer","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2024-06-01","conditions":"Nutrition Disorders, Immunotherapy, Cancer","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Megestrol Acetate and olanzapine","genericName":"Megestrol Acetate and olanzapine","companyName":"Qingdao Central Hospital","companyId":"qingdao-central-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses megestrol acetate (a progestin) to stimulate appetite and promote weight gain, while olanzapine (an atypical antipsychotic) provides additional appetite stimulation and may address underlying psychiatric or behavioral symptoms. Used for Cancer cachexia and weight loss in advanced malignancy, Appetite stimulation and nutritional support in wasting syndromes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}